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INTRODUCTION
Chronic low-grade inflammation is involved in progressive organ dysfunction in several conditions, including atherosclerosis and diabetic end organ damage. 1, 2 In solid organ transplantation, it is likely to be involved in chronic transplant dysfunction (CTD) ultimately leading to graft failure. 3, 4 In renal transplantation, CTD is a main cause of late graft failure. 3 Despite steady improvement of one-year graft survival, from approximately 40% in the 1970's to more than 90% nowadays, 5 approximately half of all cadaveric renal allografts are still lost within 10-12 years after transplantation. 6 Besides creatinine clearance and proteinuria there are, currently, no good biomarkers to establish presence of CTD and to predict the development of graft failure. 7 Biomarkers reflecting ongoing chronic low-grade inflammation could be good candidates. Procalcitonin (PCT) is best known from its potential utility as a biomarker for severe systemic inflammation, infection and sepsis. [8] [9] [10] Non-neuroendocrine parenchymal cells throughout the body (e.g. lung, liver, kidney, fat, muscle, stomach) are the principal source of circulating PCT during marked systemic inflammatory conditions. [10] [11] [12] In these conditions, hyperprocalcitonaemia often reaches high values in 8-24h, and then persists as long as the inflammatory process continues (i.e. weeks). 10 It is not known whether low steady-state concentrations of PCT under non-infectious conditions are related to chronic low-grade inflammation. Currently, circulating steady-state concentrations of C-reactive protein (CRP), determined by high sensitivity assays (hsCRP), are commonly used as biomarker for chronic low-grade inflammation. 13 We aimed to investigate whether steady-state concentrations of PCT in RTR are associated with concentrations of hsCRP and to compare predictive performance of PCT and hsCRP for development of graft failure in renal transplant recipients (RTR). As a secondary objective, we aimed to investigate whether PCT is an independent predictor of mortality.
MATERIALS AND METHODS

Research design and subject
In this prospective cohort study, all renal transplant recipients who visited our outpatient clinic between August 2001 and July 2003 and had a functioning graft for at least 1 year were eligible to participate at their next visit to the out-patient clinic. Baseline visits were postponed until symptoms had resolved in patients with fever or other signs of infection (e.g. complaints of upper respiratory tract infection or urinary tract infection). Patients diagnosed with cancer other than cured skin cancer were not considered eligible for the study. A total of 606 renal transplant recipients signed written informed consent, from an eligible 847 (72% consent rate). PCT concentration was determined in 577 RTR. Two RTR were considered extreme outliers regarding the PCT concentration and were therefore excluded from analyses, leaving 575 RTR for analyses. Further details of this study have been published previously. [14] [15] [16] [17] The Institutional Review Board approved the study protocol (METc 01/039) which was in adherence to the Declaration of Helsinki.
Outcome events
All participating subjects visited the out-patient clinic at least once a year. Information on mortality and graft failure was recorded by our renal transplant center and through close collaboration with general practitioners as well as referring nephrologists. Graft failure was defined as return to dialysis or re-transplantation and was censored for death. Graft failure and mortality of all RTR were recorded until August 2007. There was no loss to follow-up.
Renal transplant characteristics
Relevant transplant characteristics were taken from the Groningen Renal Transplant Database. This database holds information on all renal transplantations performed at our center since 1968, including dialysis history. Standard immunosuppressive treatment consisted of the following: from 1968 until 1989 prednisolone and azathioprine (100 mg/d); from January 1989 to February 1993, cyclosporine standard formulation (Sandimmune, Novartis Pharma B.V., Arnhem, The Netherlands; 10 mg/kg; trough-levels of 175 -200 μg/L in first 3 months, 150 μg/L between 3 and 12 months posttransplant, and 100 μg/L thereafter) and prednisolone (starting with 20 mg/d, rapidly tapered to 10 mg/d). From March 1993 until May 1996, cyclosporine microemulsion (Neoral, Novartis Pharma B.V., Arnhem, The Netherlands; 10 mg/kg, trough-levels idem) and prednisolone. From May 1997 to data, mycophenolate mofetil (Cellcept, Roche B.V., Woerden, The Netherlands; 2 g/day) was added from May 1997 to date. 15 Current medication was extracted from the medical record. Body mass index (BMI), waist circumference, body surface area (BSA), and blood pressure were measured as described previously. [14] [15] [16] [17] Smoking status and cardiovascular history were recorded with a self-report questionnaire. Cardiovascular disease history was considered positive if there was a previous myocardial infarction (MI), transient ischemic attack (TIA) or cerebrovascular accident (CVA).
Laboratory measurements EDTA-blood was drawn after an 8-12h overnight fasting period. PCT analyses were performed using an ultra-sensitive immunoluminometric assay (BRAHMS PCT sensitive LIA; BRAHMS Aktiengesellschaft, Hennigsdorf, Germany). 18 The assay had a functional sensitivity at 7 pg/mL, which is below the median of the normal range, and had an interassay coefficient of variation of 8% at 30 pg/mL. Concentrations of hsCRP were determined using in-house enzyme-linked immunosorbent assays as described before, 19 the lowest limit of detection was 0.002 mg/l. Plasma creatinine concentrations were determined using a modified version of the Jaffé method (MEGA AU 510, Merck Diagnostic, Darmstadt, Germany). Plasma total cholesterol, HDL cholesterol, triglycerides, and urinary protein excretion were assessed as described previously. 15 Proteinuria was defined as urinary protein excretion ≥0.5 g/24 hr. We used Homeostasis Model Assessment (HOMA) and fasting insulin concentrations as validated measures of insulin resistance [20] [21] [22] . First, in order to investigate which recipient or transplanted-kidney related characteristics were associated with PCT concentrations, we analysed these factors using linear regression analyses with log PCT concentration as dependent variable. Relations of PCT with hsCRP, creatinine clearance and proteinuria were displayed in scatter-plots with curve-fit analyses. Independent associations with PCT were established using backward linear regression analysis. Creatinine clearance, urinary protein excretion and time between transplantation and inclusion date were forced into the model to adjust for the fact that recipients at inclusion started with different allograft function and at different time points after transplantation. Additional characteristics were included if P-value was <0.05 in univariate linear regression analyses. These variables were not retained in the final model if P>0.10.
The predictive performance of plasma concentrations of PCT for graft failure and mortality was determined by generating receiver operating characteristic (ROC) curves. The area under the curve (AUC) was calculated to compare the predictive performance of PCT, hsCRP, proteinuria, and creatinine clearance for graft failure and PCT and hsCRP for mortality. Statistical differences between AUC's were compared nonparametrically by the method of DeLong et al. 23 In time to event analyses, we first investigated PCT concentrations as potential predictor of graft failure and mortality using Kaplan-Meier analyses. For these analyses we used sex stratified tertiles of PCT, because the percentages of men and women were not equally divided amongst the tertiles of PCT (1 st tertile: 41% women and 24% men; 2 nd tertile: 31% women and 37% men; 3 rd tertile: 28% women and 39% men). Second, we performed univariate and multivariate Cox regression analyses. PCT concentration was entered in the regression analyses as 2 log transformed variable, thus the HR indicates the risk per doubling of PCT concentration. We adjusted for creatinine clearance, proteinuria, and time between transplantation and inclusion date (Model 2), for recipient age and sex (Model 3), and finally for independent associates of PCT (Model 4). Secondary analyses were performed (1) with additional exclusion of RTR with hsCRP concentrations higher than 10 mg/L and (2) in nonproteinuric RTR alone.
RESULTS
A total of 575 RTR (54% male, aged 51.7±12.0 years, 84% cadaveric transplants) were analyzed. Median time between transplantation and baseline measurements was 6.1 [2.9-11.7] years. Median PCT concentration was 0.023 [0.017-0.036] ng/mL. Recipient-related and transplant-related baseline characteristics and results of univariate linear regression analyses with log PCT concentration as independent variable are shown in table 1. Of recipient-related baseline characteristics, male gender, waist circumference, current smoking, diastolic blood pressure, use of antihypertensive medication, fasting triglycerides, fasting insulin concentrations and hsCRP had significant positive associations with PCT, while HDL-cholesterol had a significant inverse association. Of transplanted kidney-related characteristics, donor age, serum creatinine, urinary proteinuria excretion, history of acute rejection and prednisolone dose had significant positive associations with PCT, while creatinine clearance had a significant inverse association. To investigate whether hsCRP is independently related to PCT, we performed a backward linear regression analysis with log PCT concentration as dependent variable and all characteristics which were significantly associated with concentrations of PCT in univariate analyses (see table 1) as independent variables. From this analysis, it appeared that hsCRP, creatinine clearance, recipient gender, urinary protein excretion, HDLcholesterol, triglycerides and donor age were independently related to PCT (table 2) According to sex-stratified tertiles of PCT (with each tertile consisting for 54% of men and 46% of women), incidence of graft failure during follow-up was 1 out of 196 (0.5%) for the lowest tertile (consisting of 106 men and 90 women), whereas this was 5 out of 190 (2.6%) and 35 out of 189 (18.5%) for the middle (consisting of 102 men and 88 women) and highest (consisting of 102 men and 87 women) tertiles respectively (P<0.0001 by logrank test, figure 2a). These numbers were 15 (7.7%), 32 (16.8%), and 44 (23.3%) respectively for incidence of mortality according to increasing sex-stratified tertiles of PCT (P=0.0001 by log-rank test, figure 2b). ROC curve analysis of the prediction of graft failure by PCT revealed a mean (SE) AUC of 0.84 (0.03). This was significantly higher than the AUC of hsCRP (0.56 (0.04), P<0.0001, figure 3a ) and similar to that of proteinuria (0.80 (0.04), P=0.4) and creatinine clearance (0.86 (0.03), P=0.6). ROC analysis of the prediction of mortality revealed an AUC of 0.66 (0.03) for PCT, which was similar to the AUC of 0.63 (0.03) for hsCRP for prediction of mortality (P=0.5 for difference, figure 3b) .
With significant associations in cross-sectional analyses and similar predictive properties in univariate prospective analyses, it is an important question whether PCT is an independent predictor of graft failure (and mortality) in multivariate analyses. Results of univariate and multivariate Cox regression analyses for late graft failure and mortality in RTR are shown in After adjustment for creatinine clearance, urinary protein excretion and time between transplantation date and inclusion date, the independent contribution of PCT to prediction of mortality decreased and remained only borderline significant (table 3, Model 2). If other variables, including hsCRP were take into account, the association of PCT with mortality was not further weakened (HR=1.4 [95%CI 1.0-1.9] per doubling PCT, P=0.05, table 3, Model 5). 
DISCUSSION
This is the first study to investigate potential value of steady-state circulating PCT concentrations for prediction of graft failure in outpatient renal transplant recipients. We found strong predictive value of PCT in addition to already existing markers such as creatinine clearance and proteinuria. Only a small part of the predictive performance of PCT was explained by baseline correlations of PCT with these factors. To the best of our knowledge, there are no other markers than PCT that are so strongly predictive of graft failure that they equal the predictive value of creatinine clearance and proteinuria. Consistent with the suggestion of PCT being an inflammatory marker, we found a significant cross-sectional association with hsCRP, but predictive performance of PCT for graft failure (and mortality) was independent of hsCRP. Furthermore, we found PCT to be particularly strong as a predictor of graft failure independent of creatinine clearance and other variables in RTR without proteinuria. All in all, our data suggest that PCT is a useful marker for non-microbial chronic low-grade inflammation in RTR.
In 1993, Assicot et al first described increased serum PCT concentrations in patients with sepsis and infection. 8 Since then, numerous studies have confirmed this observation which has lead to the notion that PCT is a marker for infection and inflammation. 9, 24 PCT concentrations are very low in healthy subjects (<0.1 ng/ml). 8, 25 In case of infection or sepsis PCT concentrations can increase rapidly up to >100 ng/mL. 25 In experiments using animal models of sepsis, it was shown that PCT was produced in non-neuroendocrine parenchymal cells throughout the body (e.g. lung, liver, kidney, fat, muscle, stomach). [10] [11] [12] More recently, it has been found that it is activated macrophages in infected tissues that stimulate parenchymal cells (e.g. adipocytes) to produce and secrete PCT during sepsis. 12, 26 PCT is not only strongly increased in response to bacterial infections and sepsis, but also in response to severe inflammatory conditions, such as inhalation injury, burn injury, pancreatitis, mechanical trauma, extensive surgery and heatstroke, in which bacterial infection may be absent. 10 There are only few studies that investigated PCT in RTR. [27] [28] [29] The consistent finding of these studies that were performed in the early phase after transplantation, that monitoring for PCT could be helpful in differentiating between infection and acute rejection. In these studies, a PCT assay with low analytical sensitivity was used, not allowing for differentiation in plasma concentrations between subjects without marked systemic inflammatory responses. 10 In contrast, we used an ultra sensitive assay with a functional sensitivity of 7 pg/mL. In cross-sectional analyses, we found significant independent associations of PCT with hsCRP, creatinine clearance, urinary protein excretion, recipient gender, HDL-cholesterol and triglycerides and donor age. There are several possible mechanisms underlying these associations. Adipocytes have been shown to secrete PCT after stimulation by activated macrophages. 12, 26 The results of several studies suggest that macrophages in adipose tissue play an important role in the relation of obesity with chronic low-grade inflammation characterized by elevated levels of inflammatory markers, including hsCRP, 15, 30 and possibly also PCT. A role for adiposity and insulin resistance would also explain the independent association of PCT with dyslipidemia that we found.
The most important finding in this study is the independent association of PCT concentrations in RTR with future development of graft failure late after transplantation. There are two potential explanations for this association. First, relatively high concentrations of PCT might reflect ongoing intrarenal alloreactivity with ongoing chronic low-grade intrarenal inflammation and progressive damage, ultimately leading to graft failure. 4 Either stimulated parenchymal cells of the kidney themselves could release PCT into the circulation in response to this ongoing inflammation or release of cytokines from kidney tissue into the circulation could induce increased chronic low-grade production and release into the circulation of PCT by other tissues, possibly including adipose tissue. 9, 10 Second, the mechanism linking increased PCT concentration to graft failure may lie in proteinuria. One of the hallmarks of proteinuric renal disease is infiltration of renal interstitial tissue by activated macrophages. [31] [32] [33] Using adipocytes as a model for parenchymal cells of all kinds of tissues, it was recently demonstrated that it was recently demonstrated that parenchymal cells secrete PCT in response to stimulation by activated macrophages. 10, 12, 26 Thus, our finding of high circulating PCT concentrations to predict graft failure may be a reflection of release of PCT into the circulation by renal parenchymal cells in response to renal macrophage infiltration and activation in relation to proteinuria. Importantly, however, in our secondary analyses, we found PCT to be particularly predictive for development of graft failure in RTR without proteinuria. One possibility is that the cascade with macrophage activation and interstitial inflammation is already fully activated when the amount of protein in urine is still below the upper limit of the reabsorption capacity of the tubular epithelial cells. There is recent evidence that much more protein is filtered than has previously been thought and that active processing by tubular epithelial cells prevents it from appearing in urine. 34, 35 The concentration of PCT will then already be elevated in RTR when proteinuria is not yet detectable. This leads to the hypothesis that PCT is not only a biomarker for the existence of proteinuria, but could also be an early marker for a tendency for development of proteinuria. The other explanation would be that PCT is an earlier and more sensitive marker for ongoing chronic low-grade renal inflammation than proteinuria, possibly related to chronic ongoing alloreactivity, for which currently no good biomarkers are available. Because development of proteinuria is a late and mostly irreversible manifestation, it would be of great value for clinical practice if future studies would find that this supposition is true. It has to be emphasized that variation in PCT concentration range found to be relevant for prediction of graft failure in our study was well below 0.1 ng/mL, which is considered as cut-off value for the presence of an infection. 25 The reported PCT concentrations can therefore only be measured using an ultra sensitive assay. Although PCT was independently associated with both graft failure and mortality, the predictive performance of PCT for graft failure was superior to the predictive performance of PCT for mortality. Furthermore, hsCRP was not a predictor for graft failure, while the predictive performances of PCT and hsCRP for mortality were similar. This observation is interesting, because it suggests different mechanisms underlying the association of PCT and hsCRP with outcomes. The prototypical acute phase reactant marker of inflammation, hsCRP, is synthesized predominantly by hepatocytes under the control of interleukin-6 (IL-6) and other inflammatory cytokines. 36 PCT, on the other hand, can be produced locally by parenchymal cells in various tissues after stimulation by activated macrophages. 10, 12, 26 The finding that PCT and hsCRP have different predicting performance for graft failure and mortality is consistent with the notion that PCT in RTR could be produced locally by inflamed renal tissue or by other tissues in response to cytokines released by renal tissue, while hsCRP is more a marker for processes related to systemic chronic low-grade inflammation, such as atherosclerosis. 36 The present study has some limitations. Several studies have investigated the pathway of PCT elimination. [37] [38] [39] [40] Most studies conclude that renal clearance is one factor that contributes to removal of PCT from plasma. To account for renal function as a possible confounder in the association of PCT with development of graft failure and mortality, we adjusted the association of PCT for creatinine clearance at baseline in a multivariate Cox-regression analysis. Nevertheless, it can not be excluded that plasma PCT concentrations did not serve as a measure of chronic low-grade inflammation in our analyses, but as an alternative and additional measure of renal function. Yet, if this would be true, it would still be a valuable additional marker to be measured, because it appeared an independent predictor of graft failure (and mortality), in particular in patients without proteinuria. Markers that are equally predictive for outcome in the general RTR population as creatinine clearance and urinary protein excretion are rare and highly desired. 7 Another limitation of our study is that we only measured PCT concentrations in baseline samples. Most epidemiological studies use a single baseline measurement to predict outcomes, which adversely affects predictive properties of variables associated with outcomes. If intra-individual variability of predictive biomarkers is taken into account, this results in strengthening of predictive properties that -despite sometimes considerable intra-individual variation day-to-day variation -also existed for single measurements of these biomarkers. 41, 42 The higher the intra-individual day-to-day variation would be, the greater one would expect the benefit of repeated measurement for prediction of outcomes. 41, 42 The day-to-day variation of PCT in RTR is not known, but it could be considerable. The estimated 50% plasma disappearance rate of t½ of PCT in the plasma is approximately 18-24hr. 39, 43 Despite the relatively short half-life of PCT, we found an increased serum PCT, within the normal range, to be a strong and independent predictor of late graft failure and to a lesser extent of mortality. This is consistent with the notion that variation at a certain time point between renal transplant recipients in plasma PCT concentrations within the normal range reflects steady-state concentrations associated with variation in chronic disease processes that ultimately lead to events distant from the time point that the plasma concentration was measured. Further, the present study is a single center study and the predictive value of PCT needs to be confirmed in other centra and/or multicenter studies. Our study includes RTR that were transplanted in multiple immunosuppressive eras. However, immunosuppressive therapy was not significantly associated with serum PCT and adjustment for immunosuppressive era in the multivariate analyses did not materially change the outcomes (data not shown). Furthermore, our study only includes stable RTR, relatively long-term after transplantation. Future studies could investigate whether PCT, measured in the early post transplant period also predicts late graft failure and mortality. Currently the Banff schema is currently used for the histologic diagnosis of rejection and is based on the histological findings in biopsies and is currently used for the histologic diagnosis of rejection. 44 However, we did not perform biopsies. It would have been very interesting if we could have stained histological sections for PCT. Apart from these limitations, our study has also an important strength in that follow-up was complete for all patients.
In conclusion, elevated plasma concentrations of PCT independently predict graft failure late after renal transplantation, in particular in RTR without proteinuria. Therefore, measurement of PCT in addition to creatinine clearance and proteinuria could be of clinical value, in particular if future studies would show that slightly elevated concentrations of PCT are indicative of chronic transplant dysfunction.
